Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Hristina Byrnes | Jun 4, 2019 at 12:31 PM EDT

This Insulin ‘Tea Bag’ May Be a Game-Changer for Diabetics

A researcher at the University of Arizona, working in collaboration with other scientists across the country and in Canada, has…

Jon C. Ogg | Jun 4, 2019 at 11:10 AM EDT

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Amgen is the largest of all biotechs now, and it is being deemed an "ASCO winner" for cancer and oncology…

Chris Lange | Jun 3, 2019 at 10:30 AM EDT

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Here is why Genocea Biosciences is one of the big winners from the annual meeting of the American Society of…

Chris Lange | May 31, 2019 at 12:00 PM EDT

Meet One of ASCO’s First Losers

Turning Point Therapeutics shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small…

Hristina Byrnes | May 30, 2019 at 2:35 PM EDT

Study: Health Care Costs Worry Americans More Than Any Other Financial Problem

As the cost of U.S. health care services and medications continue to grow at an alarming pace, Americans are now…

Chris Lange | May 30, 2019 at 12:20 PM EDT

Why Cara Therapeutics Could Rise Another 50%

Cara Therapeutics recently announced data from its late-stage trial in patients with chronic kidney disease. While there was a very…

Hristina Byrnes | May 30, 2019 at 9:49 AM EDT

These Are the States with the Best and Worst Hospitals for Patient Safety

Most people probably prefer to avoid going to the hospital if possible. It’s a choice of last resort, when we’re…

Chris Lange | May 29, 2019 at 3:51 PM EDT

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.

Jon C. Ogg | May 29, 2019 at 3:26 PM EDT

Why Credit Suisse Sees AnaptysBio Having 80% to 200% Upside

AnaptysBio has been called on to have as much as 82% upside in a Credit Suisse research report. There is…

Chris Lange | May 29, 2019 at 11:10 AM EDT

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe…

Jon C. Ogg | May 28, 2019 at 12:15 PM EDT

Goldman Sachs Crushes Value and Turnaround Hopes of Gilead Sciences

Goldman Sachs has muted any upside view by downgrading Gilead Sciences to Sell and lowering its price target.

Chris Lange | May 28, 2019 at 11:40 AM EDT

Is This Kezar Life Sciences Lupus Study in Trouble?

Kezar Life Sciences shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients…

Chris Lange | May 28, 2019 at 8:50 AM EDT

Big Pharma Short Sellers Hike Their Bets

The May 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | May 28, 2019 at 8:35 AM EDT

Major Biotechs See a Rising Tide in Short Interest

The May 15 short interest data have been compared with the previous report, and short interest in most of these…

Paul Ausick | May 24, 2019 at 4:33 PM EDT

Bad Diet Could Be to Blame for a Surprisingly High Share of Cancer Cases

New research discusses links between diet and cancer risk for Americans.

1 … 97 98 99 100 101 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

This Insulin ‘Tea Bag’ May Be a Game-Changer for Diabetics

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Meet One of ASCO’s First Losers

Study: Health Care Costs Worry Americans More Than Any Other Financial Problem

Why Cara Therapeutics Could Rise Another 50%

These Are the States with the Best and Worst Hospitals for Patient Safety

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Why Credit Suisse Sees AnaptysBio Having 80% to 200% Upside

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Goldman Sachs Crushes Value and Turnaround Hopes of Gilead Sciences

Is This Kezar Life Sciences Lupus Study in Trouble?

Big Pharma Short Sellers Hike Their Bets

Major Biotechs See a Rising Tide in Short Interest

Bad Diet Could Be to Blame for a Surprisingly High Share of Cancer Cases

Bitcoin Price Hits $80K: We Asked Grok If BTC Could Hold $80K in May

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

Bitcoin Price Hits $80K: We Asked Grok If BTC Could Hold $80K in May

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

Health and Healthcare Articles

All Health and Healthcare Articles

This Insulin ‘Tea Bag’ May Be a Game-Changer for Diabetics

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Meet One of ASCO’s First Losers

Study: Health Care Costs Worry Americans More Than Any Other Financial Problem

Why Cara Therapeutics Could Rise Another 50%

These Are the States with the Best and Worst Hospitals for Patient Safety

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Why Credit Suisse Sees AnaptysBio Having 80% to 200% Upside

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Goldman Sachs Crushes Value and Turnaround Hopes of Gilead Sciences

Is This Kezar Life Sciences Lupus Study in Trouble?

Big Pharma Short Sellers Hike Their Bets

Major Biotechs See a Rising Tide in Short Interest

Bad Diet Could Be to Blame for a Surprisingly High Share of Cancer Cases

Bitcoin Price Hits $80K: We Asked Grok If BTC Could Hold $80K in May

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up